ADPT

SEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 422,882

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000026 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 148,770

Underlying: Common Stock · 14,722 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,160

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 427,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000026 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 163,492

Underlying: Common Stock · 14,722 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 412,498

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $14.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 431,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000026 · form4.xml · derivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,214

Underlying: Common Stock · 14,722 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 416,836

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000026 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 435,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000024 · form4.xml · derivative · entry 14

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 192,936

Underlying: Common Stock · 6,613 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F9 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780664-26-000024 · form4.xml · derivative · entry 13

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,109 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 421,174

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 424,512

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 433,621

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000024 · form4.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,109

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 425,512

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 425,912

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 444,572

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000024 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,831

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 429,850

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 431,950

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000024 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 448,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780649-26-000011 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,180,518

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 391,658

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000022 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,553

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 434,188

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 434,288

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $15.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 465,129

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 453,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780660-26-000013 · form4.xml · derivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,297

Underlying: Common Stock · 2,344 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000013 · form4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,154

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000013 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780851-26-000011 · form4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,512,058

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $14.65 to $15.06, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,275

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 438,526

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.39 to $13.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 457,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780649-26-000011 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,217,781

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,997

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 442,864

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000022 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 461,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000020 · form4.xml · derivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,719

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 447,202

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 466,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000020 · form4.xml · derivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,441

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 451,540

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000020 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 470,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000018 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,163

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,878

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.10 to $13.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.